Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.

doi:10.1158/1078-0432.CCR-12-0605

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2012

Gavin Patrick G, Colangelo Linda H, Fumagalli Debora, Tanaka Noriko, Remillard Matthew Y, Yothers Greg, Kim Chungyeul, Taniyama Yusuke, Kim Seung Il, Choi Hyun Joo, Blackmon Nicole L, Lipchik Corey, Petrelli Nicholas J, O'Connell Michael J, Wolmark Norman, Paik Soonmyung, Pogue-Geile Kay L

Abstract excerpt

PURPOSE: The purpose of this study was to examine the prognostic and oxaliplatin predictive value of mismatch repair (MMR) status and common hot spot mutations, which we previously identified in stage II and III colon cancer. EXPERIMENTAL DESIGN: Mutations in BRAF, KRAS, NRAS, MET, and PIK3CA were profiled in 2,299 stage II and III colon tumors from National Surgical Adjuvant Breast and Bowel Project (NSABP)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Mismatch Repair

Share to Microsatellite Instability

Share to Mutation Rate

Share to Neoplasm Staging

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 23045248
DOI: 10.1158/1078-0432.CCR-12-0605
PMCID: PMC4273673

Genes

BRAF
KRAS
MET
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.PMID 23045248Read ↗

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.Semantic proximity Read ↗

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.Semantic proximity Read ↗

Prognostic and predictive molecular biomarkers in advanced colorectal cancer.Semantic proximity Read ↗

Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.Semantic proximity Read ↗

Identification of MKI67, TPR , and TCHH Mutations as Prognostic Biomarkers for Patients With Defective Mismatch Repair Colon Cancer Stage II/III.Semantic proximity Read ↗

Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy.Semantic proximity Read ↗

Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.Semantic proximity Read ↗

Implications of mismatch repair-deficient status on management of early stage colorectal cancer.Semantic proximity Read ↗

Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).Semantic proximity Read ↗

Promising New Agents for Colorectal Cancer.Semantic proximity Read ↗

An Insight Into the Driver Mutations and Molecular Mechanisms Underlying Mucinous Adenocarcinoma of the Rectum.Semantic proximity Read ↗

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.